^
Association details:
| Biomarker: | RSPO3 fusion |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + CGX1321 (Wnt signalling pathway inhibitor, PORCN inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.
Published date:
05/25/2023
Excerpt:
Of the 6 pts in the roll-over cohort, 3 pts with RSPO3 fusion tumors achieved PR during CGX1321 + pembro combination therapy....CGX1321 has demonstrated potent inhibition of the WNT pathway with manageable side effects. Promising efficacy signals have been observed in pts whose tumors harbor RSPO fusion, supporting further development of CGX1321 monotherapy and CGX1321 + anti-PD-1/L1 in a defined patient population that is historically known to be refractory to standard therapies and immune checkpoint inhibitors.
DOI:
10.1200/JCO.2023.41.16_suppl.3514
Trial ID:
